Eli Lilly announced on Wednesday that it has initiated legal action against several wellness vendors. The company has filed six lawsuits, aiming to stop the unauthorized sales of its potent experimental weight-loss drug, retatrutide. These vendors are accused of distributing illegal versions of the drug online.
This move reflects Eli Lilly’s effort to control the market and ensure that only legitimate and approved versions of retatrutide are available to the public. The company is determined to combat the flood of illicit sales, which pose a risk to consumers and compromise the integrity of their research and development processes.